Commentary|Videos|February 4, 2025
SCOPE Summit 2025: Advarra’s Ashley Davidson Highlights Current Challenges with Study Startup
Author(s)Andy Studna, Senior Editor
In an interview with ACT senior editor Andy Studna at SCOPE Summit, Davidson, vice president, product lead - sponsor tech strategy, Advarra, discussed ongoing challenges in study startup processes, including contract and budget issues, and feasibility concerns, which have persisted for over a decade.
Advertisement
ACT: What are some current challenges with study startup and how can they be addressed?
Davidson: Unfortunately, we have a lot of the same challenges today in study startup that we were talking about 10 or 15 years ago. We still as an industry, are aware of the longest pole in the tent, which is contracts and budgets. We know feasibility is a challenge, but I would actually add another challenge today that's even more pervasive than ever before, and that is the lack of collaboration in study startup and a lack of site centricity. I think that's really important to consider the site as a very big stakeholder in the study startup process. Study startup is not just a transaction where you're needing to get things from sites and get those back, they actually want to be an active part of it, and also need the same amount of visibility into those critical path milestones as sponsors do.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
- Q&A: Strategies for Successful Global Clinical Trial Delivery
September 12th 2025
- Vabysmo Shows Long-Term Efficacy and Safety in Wet AMD, PCV Patients
September 12th 2025
- Latest NIMBLE Study Results Highlight Progress in gMG Research
September 12th 2025
- ACT Brief Episode 8: Expert Insights on the Future of Obesity Drug Trials
September 11th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
FDA Fast Tracks Sanofi’s Intravitreal Gene Therapy for Neovascular Age-Related Macular Degeneration
2
Phase III BRUIN CLL-313 Trial Finds Jaypirca Extends Progression-Free Survival in Treatment-Naïve CLL/SLL
3
Latest NIMBLE Study Results Highlight Progress in gMG Research
4
ACT Brief Episode 8: Expert Insights on the Future of Obesity Drug Trials
5